AstraZeneca to present new data on monalizumab in combination with durvalumab in a late-breaking abstract on COAST Phase 2 trial Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the...

Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced that members of its senior management team are scheduled to participate in the...

Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or “AMF”) General Regulation...

Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or “ AMF ”) General Regulation...

Investigator-sponsored FORCE trial did not meet primary endpoints Company will stop exploring avdoralimab in COVID-19 Investigator-sponsored avdoralimab clinical trial in inflammation will continue...

First data set from TELLOMAK establishes safety, clinical responses and skin improvement in patients with mycosis fungoides that express KIR3DL2 Data support continued development of lacutamab for...

Company to highlight lacutamab data in mycosis fungoides and share data on its next-generation NK cell engager platform, ANKET™ Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA...

Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or “AMF”) General Regulation...